Life Science Investing Defence to Present New Scientific Data on Its ADC-Enhancing Accum Technology at the World ADC Conference in San Diego, USA, November 4-5, 2025
Life Science Investing Defence Therapeutics to Attend CPHI Worldwide in Frankfurt, October 28-30, 2025
Life Science Investing Defence Therapeutics Appoints Dr. Mark Lambermon as Head of Quality and Operations
Life Science Investing Defence Therapeutics Completes Fully Subscribed Debenture Units Financing of $2,000,000
Life Science Investing Defence Therapeutics Engages Dr. Amie Phinney as Strategy & Business Advisor to Guide Next Phase of Growth
life science investing RETRANSMISSION: Defence Breakthrough: Successfully Engineered Accum-mRNA Vaccine Creating a New Vaccine Platform. The in vivo Accum-mRNA Cancer Vaccine Program Begins
life science investing Defence Breakthrough: Successfully Engineered Accum-mRNA Vaccine Creating a New Vaccine Platform. The in vivo Accum-mRNA Cancer Vaccine Program Begins
life science investing Defence to Complete a Final Pre-Clinical Study Prior to IND Filings for the AccuTOX Phase I Cancer Trial at the City of Hope National Medical Center and Beckman Research Institute
life science investing Defence Therapeutics Announces Exercise of Warrants for Gross Proceeds of over $5 Million
